Investors of Soleno Therapeutics Prepare for Class Action Over Securities Fraud Allegations

Rosen Law Firm, a renowned global entity specializing in investor rights, has brought forth a reminder to shareholders of Soleno Therapeutics, Inc. regarding a significant opportunity to engage in a class action lawsuit due to purported securities fraud. The firm emphasizes that individuals who acquired shares of Soleno's common stock between March 26, 2025, and November 4, 2025, may be entitled to compensation without incurring any upfront costs.

Important Details for Investors

The Rosen Law Firm has set a deadline of May 5, 2026, for investors wishing to take the lead in this class action. According to the firm, those purchasing Soleno's stock within the specified time frame may join the legal efforts without bearing any immediate financial burdens through a contingency fee arrangement.

For individuals interested in joining the lawsuit, they can directly access the registration link at their website, or they may contact Phillip Kim, Esq. by calling toll-free at 866-767-3653 or reach out via email at [email protected]. The class action has already been formalized, and prospective lead plaintiffs must file their motions by the set deadline to represent fellow shareholders in the ongoing litigation.

The Case Against Soleno Therapeutics

The lawsuit centers on allegations that Soleno Therapeutics disseminated misleading statements or failed to adequately disclose critical safety concerns regarding their Phase 3 clinical trial for diazoxide choline extended-release tablets (DCCR). Specific claims include that the company downplayed and concealed significant safety risks associated with DCCR, particularly concerning fluid retention in trial participants. These issues raised questions about the viability of DCCR as a treatment for hyperphagia in individuals suffering from Prader-Willi syndrome (PWS).

As the truth about these risks emerged, investors reportedly experienced significant losses. The case highlights the vulnerabilities faced by shareholders when companies fail to provide transparent and accurate information regarding the commercial viability and safety of their products.

A Call to Action

Rosen Law Firm underscores the importance of choosing legal representation with a proven track record in securities class action lawsuits. Notably, the firm has previously recovered substantial settlements for investors, including the largest-ever settlement against a Chinese company in the history of such cases. Their attorneys have received accolades for their expertise and success, making the firm a reputable choice for those looking to join the suit.

For potential plaintiffs, it is crucial to understand that until a class is formally certified, they are not represented legally unless they procure counsel. Affected investors can remain as absent class members or may opt to select their own legal representatives.

Stay Updated

For continued updates throughout the legal proceedings, investors are encouraged to follow the Rosen Law Firm on their social media channels including LinkedIn, Twitter, and Facebook. The engagement of a knowledgeable legal team can significantly influence the outcome of the case, ensuring the interests of all participants are duly represented as these developments unfold.

Conclusion

The opportunity presented by the Rosen Law Firm is significant for investors of Soleno Therapeutics, prompting them to take action before the impending deadline. Engaging in this class action not only allows participants to seek justice for alleged securities fraud but also fosters a collective effort towards corporate accountability in the pharmaceutical sector.